# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
The FDA has approved Verona Pharma's Ohtuvayre (ensifentrine) as maintenance treatment of chronic obstructive pulmonary dis...
Canaccord Genuity analyst John Newman maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and maintains $1152 price...
The trial showed a greater proportion of those receiving weight-tiered higher dose Dupixent experienced significant improvement...
Argus Research analyst Jasper Hellweg maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price targ...
Regeneron Pharmaceuticals released data from a Phase 1 study on garetosmab and trevogrumab at the ADA meeting, showing signific...
RBC Capital analyst Brian Abrahams reiterates Regeneron Pharmaceuticals (NASDAQ:REGN) with a Outperform and maintains $1229 ...
Biotech investing is risk-fraught but the returns could be staggering if one chooses to take the educated approach.